Life Sciences News | BioTuesdays by Kilmer Lucas IR

Developments

Greenwich adds Harvard and Johns Hopkins sites to Phase 3 trial

Greenwich LifeSciences (NASDAQ:GLSI) has announced the launch of two new clinical sites for its FLAMINGO-01 Phase 3 trial of GLSI-100 in HER2 breast cancer, including Harvard and Johns Hopkins Universities...

January 23, 2025

Developments

EMA grants IRLAB waiver from pediatric studies of mesdopetam in PD

IRLAB Therapeutics (STO:IRLAB-A; FRA:6IRA) has announced that the European Medicines Agency (EMA) has granted a waiver allowing the company to bypass pediatric studies of mesdopetam, enabling a focus on patient groups...

January 23, 2025

Developments

IPA’s AI-designed GLP-1 therapies aim to improve treatment for T2D

IPA (ImmunoPrecise Antibodies) (NASDAQ:IPA) has announced the development of a new class of GLP-1 therapies—leveraging AI—to enhance the efficacy, safety, and longevity of treatments for Type 2 diabetes (T2D) and...

January 22, 2025

Developments

FDA grants RPDD to MeiraGTx’s treatment for LCA1

MeiraGTx (NASDAQ:MGTX) has announced that its AAV8-RK-RetGC program for the treatment of patients with Leber congenital amaurosis due to GUCY2D mutations (LCA1) has been granted Rare Pediatric Disease Designation (RPDD)...

January 22, 2025

Executive Moves

Biodexa names Dr. Gary A. Shangold as CMO

Biodexa Pharmaceuticals (NASDAQ:BDRX) has announced the appointment of Dr. Gary A. Shangold as chief medical officer (CMO), effective immediately. The company stated that Dr. Shangold brings extensive experience across...

January 22, 2025

Developments

Revelation launches Phase 1b study of Gemini in CKD

Revelation Biosciences (NASDAQ:REVB) has announced the commencement of its PRIME Phase 1b clinical study evaluating escalating doses of Gemini, its intravenously administrated proprietary formulation of phosphorylated...

January 21, 2025

Developments

Nanobiotix doses first patient in Phase 2 study of radioenhancer in NSCLC

Nanobiotix (NASDAQ:NBTX; Euronext:NANO) has announced the dosing of the first patient in its CONVERGE Phase 2 study, evaluating its potential first-in-class radioenhancer, JNJ-1900 (NBTXR3), in patients with stage 3 non...

January 21, 2025

Developments

BioNxt moves R&D to Gen-Plus in Munich

BioNxt Solutions (CSE:BNXT; OTC:BNXTF; FSE:BXT) has announced that it will transition its research and development activities to Gen-Plus, a contract research and development organization in Munich, Germany, effective...

January 21, 2025

Developments

R&M features Izotropic in US breast cancer analysis and forecast

Izotropic (CSE:IZO; OTCQB:IZOZF; FSE:1R3) announced its inclusion in a Research and Markets (R&M) report analyzing the US breast cancer screening and diagnostic market. According to Izotropic, the R&M analysis...

January 17, 2025

Developments

Evaxion completes dosing of personalized vaccine for advanced melanoma

Evaxion Biotech (NSADAQ:EVAX) has announced the completion of dosing for 16 patients in a Phase 2 trial of its lead asset, EVX-01, a personalized cancer vaccine under development for advanced melanoma. According to...

January 16, 2025

Developments

Avicanna and Vectura forge scientific and medical affairs collaboration

Avicanna (TSX:AVCN; OTCQX:AVCNF; FSE:ONN) has announced a scientific and medical affairs collaboration with Vectura Fertin Pharma to establish a joint committee aimed at enhancing the understanding of medical cannabis...

January 16, 2025

Developments

OS Phase 2b trial of immunotherapy candidate achieves primary endpoint with statistical significance

OS Therapies (NYSE-A:OSTX) has announced positive data from its Phase 2b clinical trial of OST-HER2, its targeted immunotherapy candidate, in the rare, pediatric-designated indication of preventing recurrent, fully...

January 15, 2025

Greenwich adds Harvard and Johns Hopkins sites to Phase 3 trial

EMA grants IRLAB waiver from pediatric studies of mesdopetam in PD

IPA’s AI-designed GLP-1 therapies aim to improve treatment for T2D

FDA grants RPDD to MeiraGTx’s treatment for LCA1

Biodexa names Dr. Gary A. Shangold as CMO

Revelation launches Phase 1b study of Gemini in CKD

Nanobiotix doses first patient in Phase 2 study of radioenhancer in NSCLC

BioNxt moves R&D to Gen-Plus in Munich

R&M features Izotropic in US breast cancer analysis and forecast

Evaxion completes dosing of personalized vaccine for advanced melanoma

Avicanna and Vectura forge scientific and medical affairs collaboration

OS Phase 2b trial of immunotherapy candidate achieves primary endpoint with statistical significance

General

More